PolyPeptide Group targets €1.5bn valuation
Swiss pharmaceutical ingredients manufacturing company PolyPeptide Group has filed for an IPO on the SIX Swiss Exchange, which is expected to value the company at around €1.5bn equivalent to €1.7bn equivalent, according to a source close to the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: